Bexson Biomedical

Bexson Biomedical is a pre-revenue, private biotech developing a novel drug delivery platform centered on its patented SeVALENT™ technology, a 7-valence salt system that enhances the solubility and subcutaneous delivery of small molecules. The company is leveraging this platform to repurpose existing drugs, such as ketamine and flumazenil, for at-home use via a wearable pump, while also exploring new chemical entities. With a focus on pain, addiction, and mental health, Bexson aims to de-risk development, extend patent lifecycles, and improve health economics through remote care.

SeVALENT™: A patented 7-valence salt technology using sulfobutylether-β-cyclodextrin (SBE-β-CD) as a counterion to create highly soluble formulations for subcutaneous delivery of ionizable small molecules. It solves formulation challenges of pH, osmolality, and volume.

Bexson competes with other drug delivery and reformulation companies, as well as developers of novel psychedelic and addiction therapies. Its specific combination of a broad salt-forming platform and a dedicated wearable pump partnership is distinctive, but it faces competition from companies developing oral, intranasal, or other parenteral formulations of similar compounds like ketamine and DMT.